Crossmark

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia

Crossref DOI link: https://doi.org/10.1016/j.medcle.2021.03.036

Published Print: 2022-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Cardona-Pascual, Ignacio http://orcid.org/0000-0003-4153-946X
Berlana, David http://orcid.org/0000-0001-5772-7284
Martinez-Valle, Ferran http://orcid.org/0000-0003-2673-2034
Campany-Herrero, David http://orcid.org/0000-0002-5778-6038
Montoro-Ronsano, José Bruno http://orcid.org/0000-0003-4390-2189
License Information

Text and Data Mining valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01

stm-asf valid from 2022-04-01
More Information

This article is maintained by: Elsevier

Article Title: Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2021.03.036

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2021.03.005

Content Type: article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.